Two hundred fifty patients with knee osteoarthritis were randomized to receive either flurbiprofen cataplasms (FPC) (n=124) or loxoprofen sodium cataplasms (LSC) (n=125) for 28 days. The primary outcome of interest was the change in pain intensity measured by the visual analog scale (VAS) from baseline to day 28. Secondary outcomes included the extent of pain relief, changes in joint function assessed by the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), adverse events, and the trend of VAS score changes over time. Outcomes were assessed at baseline and weeks 1, 2, and 4. Overall, the results revealed that FPC provided superior pain relief compared to LSC, with a significantly greater reduction in VAS scores, improved WOMAC scores, and a lower incidence of adverse events. These findings suggest that FPC may be a more effective and safer option for knee osteoarthritis pain management than LSC.